Amgen, Janssen reach settlement on Stelara biosimilar drug, allowing for 2025 launch at latest
Amgen and Janssen settled their lawsuit over a biosimilar option to J&J’s blockbuster biologic Stelara — paving the way for the newer drug to enter the market.
Amgen told Endpoints News in a statement that the terms of the settlement, which were announced Monday via a court filing, remain confidential. However, Amgen will be allowed to launch its Stelara biosimilar “no later than January 1st, 2025.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters